Fabino Enterprises Ltd (BSE: FABINO.BO) AI-Powered Stock Analysis
See how Fabino Enterprises Ltd scores across key metrics like financial growth, valuation, and market position on the BSE, using AI-driven evaluation.
FABINO.BO●BSE
HealthcareMedical - Pharmaceuticals
₹20.31
₹0.96(4.96%)
Indian Market opens in 6h 37m
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continuously improving this model to increase accuracy and performance.Read our Full DisclaimerFabino Enterprises Ltd (BSE: FABINO.BO) Stock Overall Grade
Fabino Enterprises Ltd's grade for its BSE listing, based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Fabino Enterprises Ltd's overall BSE stock rating.
Forecast
C+Score
59/100Financial Growth
CScore
40/100Fundamental Growth
C+Score
50/100Key Ratios
C+Score
59/100Sector Comparison
B+Score
75/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
98/100Analyst Consensus
C+Score
50/100Fabino Enterprises Ltd (BSE: FABINO.BO) AI-Powered Stock Analysis
On the BSE, FABINO.BO demonstrates Good performance with an overall Forecast Score of 59/100 (C+), reflecting weak confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (50/100, C+) highlight its stability, while Key Ratios (59/100, C+) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (98/100, A+), the BSE-listed stock shows competitive strength. Analyst Consensus (50/100, C+) suggests High divergence in outlook.(BSE: FABINO.BO) Component Analysis Explained
Understand the key factors behind each Fabino Enterprises Ltd (BSE: FABINO.BO) stock grade, including financials, comparisons, and forecasts.